Dallas Weekly is reporting Darnisha Harrison, founder and CEO of Atlanta-based Ennaid Therapeutics, which develops anti-viral treatments, filed a patent for a Coronavirus treatment developed by scientists at her company. The article states:
“Both BET News and WBRZ-TV, an ABC News affiliate in Baton Rouge, have confirmed that Harrison, who graduated from Louisiana State University, has already filed a patent after discovering a drug that shows strong scientific evidence of blocking two proteins that cause COVID-19 from invading healthy host cells and replicating. The drug is called ENU200, a repurposed, patent-pending, orally deliverable antiviral drug that was previously approved by the U.S. Food and Drug Administration (FDA) for a different indication.”
Harrison, a former microbiologist and chemist who initially began working in veterinary medicine, spent three years as a scientist at Amgen and the University of Georgia, and sixteen years in Business Development/Licensing as a Director in various companies within the pharmaceutical research & development industry. She has been profiled by Newsweek Magazine for her work on finding a cure for the Dengue virus.
In an interview with Chris Nakamoto of WBRZ news, Harrison believes if the patent is approved, Ennaid can start clinical trials in approximately 90 days which would last for roughly one month. Harrison also said the FDA has been supportive with fast-tracking the review process for the treatment.
This story is developing. Find out more about Ennaid Therapeutics here.
Find out more about Darnisha Harrison here.
Follow The Burton Wire on Twitter @TheBurtonWire.